Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients

Eur J Cancer. 2022 May:167:175-176. doi: 10.1016/j.ejca.2022.02.032. Epub 2022 Mar 15.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • COVID-19 Vaccines / adverse effects
  • COVID-19* / prevention & control
  • Humans
  • Neoplasms*
  • RNA, Messenger
  • SARS-CoV-2
  • Seroconversion

Substances

  • COVID-19 Vaccines
  • RNA, Messenger